and the sap fell for it.
Now there are 160M shares outstanding ...... the share price should be under $1.00 now ..... some more air needs to be taken out of the pumped up DreramTeam bubble.
"Concerns have also been raised about the risk of serotonin syndrome in pregnant women who take a selective serotonin reuptake inhibitor (SSRI) and Zofran or another 5-HT3 receptor antagonist at the same time. The concern is that both types of medication modify the amount of serotonin in the patient's brain, which could lead to serotonin syndrome, a potentially fatal condition. Symptoms of serotonin syndrome include confusion, agitation, lethargy, coma, hyperthermia, nausea, vomiting and tremors.
According to a report from the FDA, as of February 13, 2013, the agency had received 39 reports of serotonin syndrome linked to ondansetron."
"In 2011, the FDA issued a warning that use of Zofran could result in an abnormal heart rhythm, including QT interval prolongation and Torsade de Pointes. The FDA advised patients with congenital long QT syndrome should not be treated with Zofran. Additionally, the agency required GlaxoSmithKline to conduct a thorough QT study to determine the degree of risk."